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Clinicala b s t r a c t
The objectives of this clinical study were to evaluate changes in tobacco product use behavior and levels
of selected biomarkers of exposure (BOEs) for smokers who switched to one of six conditions during clin-
ical conﬁnement: exclusive use of; Camel Snus, Sticks, Strips or Orbs, controlled Dual use of cigarettes and
Camel Snus, or tobacco abstinence. The controlled Dual use (DU) condition mandated a 60% reduction in
cigarettes smoked per day (CPD). 167 healthy U.S. male and female smokers were randomized to the six
groups (n = 25–30/group). Subjects smoked their usual brand of cigarette for 1 day prior to switching to
their designated intervention condition. Levels of thirty-two BOEs in plasma, whole blood, urine and feces
were determined before and after switching. Questionnaires that scored nicotine dependence and with-
drawal discomfort were also administered. After 5 days, exclusive Snus, Sticks, Strips, or Orbs use aver-
aged 6.1, 5.9, 13.5, and 8.5 units/day, respectively. DU subjects smoked 7.6 CPD and used 3.2 Snus
pouches/day, on average. After 5 days, substantial reductions of most biomarkers, including nicotine,
were observed in all groups. Toxicant exposures were similar to being tobacco abstinent after switching
exclusively to Camel Snus, Sticks, Strips or Orbs. DU reductions were more modest.
 2015 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction combustion-related toxicants. As such, the risks for serious diseaseIn recent years, the tobacco industry, including R.J. Reynolds
Tobacco Company (RJRT), has introduced smokeless tobacco prod-
ucts containing reduced levels of harmful and potentially harmful
constituents (HPHCs) present in cigarette smoke. Camel Snus and a
relatively new tobacco product category, referred to as dissolvable
tobacco products (DTPs), that includes Camel Sticks, Strips, and
Orbs are examples of such products. Snus comes in a portioned
pouch. It is placed between the cheek and gum for about
20–30 min and does not require spitting. Camel DTPs are intended
to be placed in the mouth until completely dissolved or dispersed
and entirely consumed, and also do not require spitting. While no
tobacco product has been shown to be safe and without risks, the
increased risk of harm from tobacco use is generally recognized to
proceed along a pronounced continuum; signiﬁcantly inﬂuenced
by the type of tobacco product, its associated toxicant proﬁle,
and the manner and frequency of use (Zeller et al., 2009; Zeller,
2013). Products that burn tobacco during use produce tobaccoare greatest with combustible tobacco products.
The objectives of this clinical trial were to characterize tobacco
product use patterns and subjective responses, estimate daily
mouth-level exposure (MLE) to ‘tar’ and/or nicotine, and to
quantify levels of select biomarkers of tobacco or tobacco smoke
exposure in biological specimens after smokers are switched for
a 5-day period to one of six groups: exclusive use of Snus, Sticks,
Strips, or Orbs, Dual use of cigarettes and Snus (Dual use), or smok-
ing/tobacco abstinence (Abstinent). The Abstinent group was
included to determine the maximum declines possible for bio-
marker responses under the trial conditions utilized. The biomark-
ers of exposure selected for analysis represent toxicants which
have been identiﬁed as hazardous or potentially hazardous, and
shown in other clinical intervention trials to change when cigarette
smokers signiﬁcantly change their smoking behavior, switch to the
use of tobacco products with lower toxicant levels or abstain from
tobacco use (Sarkar et al., 2009; Breland et al., 2006; Hatsukami
et al., 2004; Mendoza-Baumgart et al., 2007).
2. Materials and methods
This trial was a randomized, controlled, open-label, parallel
group study design, conducted by Covance Clinical Research Unit
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ville, IN, and Madison, WI, with the clinical phase performed
between September, 2010 and February, 2011. The trial was
approved by Independent Institutional Review Board, Inc.
(currently Shulman Associates IRB, Inc., Fort Lauderdale, Florida
USA) and was conducted in accordance with Good Clinical Practice,
Financial Disclosure by Clinical Investigators and Institutional
Review Boards and consistent with the Declaration of Helsinki.
All participants signed informed consent before any trial proce-
dures were performed and were paid for their participation.
2.1. Participants
Generally healthy adult male and female smokers between the
ages of 21 and 65 were recruited by local radio, TV and printed
advertisement. Potential enrollees were prescreened by phone
and those eligible asked to make two screening visits within a
28-day period. Primary inclusion criteria required: a self-report
of smoking P10 cigarettes/day for P12 months (menthol or non-
menthol; high or medium machine measured ‘tar’ yield), a Fag-
erström test for nicotine dependence (FTND) score P3 (minimal
dependence or higher) (Heatherton et al., 1991). Primary exclu-
sionary criteria were: use of any nicotine-containing products
other than cigarettes within 30 days prior to trial, evidence of drug
abuse, a serious medical condition, current oral lesions, or being or
becoming pregnant or breast feeding. Participants with chronic
diseases whose symptoms were controlled by oral medication(s)
(e.g., diabetes or hypertension) were enrolled if deemed acceptable
by the principle investigator.
During the ﬁrst screening visit enrollees signed informed con-
sent, had their urine cotinine level measured (passP 200 ng/mL)
and were asked to ‘taste-test’ one of each of the four test products
for palatability. If acceptable, enrollees had a physical and oral exam
and provided demographic and medical history information. Urine
and blood specimens were collected for standard screenings (clini-
cal chemical series-20, hematology, urinalysis, pregnancy, FSH and
estradiol, hepatitis, HIV, urinary illicit drugs and alcohol breathaly-
zer) and the FTND was administered and scored. During the second
visit, vital signs and expired carbon-monoxide (ECO)measurements
were made, clinical laboratory results reviewed and eligibility
determined. Participants were randomized into one of six groups
(but were blinded to their assigned group until ﬁrst day of new con-
dition) and scheduled for clinic check-in. Participants were
informed they could leave the trial at any time for any reason with-
out penalty, and if they wanted to quit smoking, they were encour-
aged to discuss treatment options with their private physician.
2.2. Test products
Participant usual brand (UB) cigarettes were provided by the
clinical sites and purchased locally at retail outlets. Both menthol
and non-menthol brands were allowed.
Camel Snus (Snus) is consistent in form and general composi-
tion to other commercial products referred to as ‘‘Swedish snus’’,
primarily available in Scandinavian countries. It is widely accepted
that Swedish snus, while addictive, is less risky than cigarettes and
may lower risks of tobacco-related diseases (e.g., WHO, 2008;
European Commission, 2008; Le Houezec et al., 2011). The Snus
tested in this trial was made as individual 600-mg pouches, with
a moisture content of 30%, and a total alkaloid content of
6.9 mg/pouch. Nicotine is the primary tobacco alkaloid, compris-
ing about 95% of the total alkaloid content (Benowitz et al., 2009).
On a dry-weight basis (dwb), Snus is mainly comprised of tobacco,
with the pouch material and food-grade minor ingredients
accounting for the remainder: sodium carbonate, sodium
bicarbonate, sucralose, propylene glycol, salt, and natural and/orartiﬁcial ﬂavors. The relatively low salt content in Snus minimizes
salivation and the need to spit. In this trial, two Snus variants were
available for participant selection; Frost (mint) or Mellow (non-
mint). Both variants were comprised of the same tobacco blend
and substantially similar formulations, differing primarily in the
proprietary ﬂavor mixture used. Because ﬂavor mixtures account
for relatively small proportions of the ﬁnal products, both variants
are considered equivalent in nature and composition for the pur-
pose of this study.
The Sticks, Strips, and Orbs tested are generally similar in com-
position and consist of ﬁnely-milled tobacco and other food-grade
ingredients that include: binders, ﬁllers, acid–base modiﬁers, pro-
cessing aids, humectants, colorants, artiﬁcial sweeteners, and natu-
ral and/or artiﬁcial ﬂavors. Having some differences in non-tobacco
ingredients, Sticks, Strips, and Orbs in this study differ primarily by
their physical attributes (unit weight, shape, size, and dissolution
time) and organoleptic characteristics (texture and taste). Sticks,
Strips, and Orbs are low moisture products having a unit weight
of approximately 486, 207, and 227 mg, and a total alkaloid content
of approximately 3.2, 1.0, and 1.1 mg, respectively.
Given tobacco blend selection, other food-grade ingredients and
manufacturing conditions, all products tested in this trial had rel-
atively low concentration levels of select toxicants (i.e., total
tobacco-speciﬁc nitrosamines (TSNAs), polycyclic aromatic hydro-
carbons (PAHs), aromatic amines (AAs), and metals).
2.3. Trial design and conduct
Trial conduct conﬁned participants on an on-going rotational
basis until total enrollment required per group (n = 25) was
achieved. Five to 14 participants were conﬁned/rotation/site;
check-in occurred the day before baseline (D -2), followed by base-
line day (Day -1), followed by Days 1–5 of intervention. The follow-
ing morning after Day 5 (Day 6) participants completed procedures
and were discharged after medical approval. Six rotations were
required to complete enrollment at each of the three clinical sites,
with 73, 30, and 64 completed participants recruited at the Day-
tona, Evansville, and Madison sites, respectively. During conﬁne-
ment, participants were offered meals and snacks that excluded:
grilled, charbroiled or barbequed foods (potential sources of PAHs
and AAs) and full-bodied beer, almonds and kale (potential sources
of cyanogens). Participants could elect to drink up to two alcoholic
beverages (12-oz ultralight beer or 6-oz of white or rose wine per
serving) during evening meals. Tobacco product usage was unre-
stricted (except as noted) although site staff dispensed all products
(one cigarette or Sticks, or one or two Snus, Strips or Orbs) between
the hours of 07:00 and 23:00 whenever requested. Each site had a
sheltered outdoor smoking area and participants wore color-coded
wrist-bands to facilitate staff surveillance of proper product use.
During baseline day, all participants smoked as many UB ciga-
rettes as desired until 23:00. Their daily consumption, i.e., ciga-
rettes per day (CPD) was determined based upon the number of
cigarettes smoked during baseline day. As a precautionary measure
to prevent the potential for signiﬁcantly increased nicotine expo-
sure, a product maximum-use-level (MUL) was calculated for each
participant that limited their total daily tobacco usage to 130% of
their baseline cigarette consumption. For this purpose, one ciga-
rette was considered a single unit of exposure (i.e., 1.0–1.25 mg
nicotine exposure assumed). Based on the nicotine content of the
4 products tested and assuming bioavailability of 50% for Snus
and 100% for the DTPs: SNUS and Sticks = 2 units each and Orbs
and Strips = 1 unit each. All participants were encouraged during
informed consent to use as much of their assigned product as they
may wish, but not to exceed their MUL. The morning after baseline
day, participants started their assigned intervention as a member
of one of six groups:
188 G.R. Krautter et al. / Regulatory Toxicology and Pharmacology 71 (2015) 186–1971. Dual use group (Dual use): Participants were allowed to continue
to smoke their UB cigarettes at any time, but restricted to a
maximum of 40% of their baseline CPD. These participants were
also allowed to consume as many Snus pouches as they wanted
at any time, but not while smoking.
2. Exclusive Snus group (Snus): Participants discontinued smoking
entirely and switched to consuming as many Snus pouches as
they wanted.
3. Exclusive Sticks group (Sticks): Participants discontinued smok-
ing entirely and switched to consuming as many Sticks as they
wanted.
4. Exclusive Strips group (Strips): Participants discontinued smok-
ing entirely and switched to consuming as many Strips as they
wanted.
5. Exclusive Orbs group (Orbs): Participants discontinued smoking
entirely and switched to consuming as many Orbs as they
wanted.
6. Tobacco Abstinent group (Abstinent): Participants discontinued
smoking/tobacco use entirely.
All participants had unrestricted access to standard and sugar-
less hard candies and gum. Throughout the conﬁnement period
all tobacco product use was voluntary.2.4. Filter processing and mouth-level exposure (MLE) estimates
Smoked cigarette ﬁlter processing: The cigarette butt length is
deﬁned as the length of unburnt cigarette remaining at the
moment when the cigarette is extinguished or stops smoldering.
As such, the ﬁnal cigarette butt length results from the cigarette
burning down to a shorter length during active smoking and, in
some cases if the cigarette is not extinguished at the end of active
smoking, from additional reduction in length due to smoldering.
All individual cigarette butts collected during the trial had their
butt lengths measured (mm) with a standard ruler. Then 10-
mm ﬁlter segments were cut and composited into daily samples
for analysis of the amounts of ‘tar’ and nicotine that passed
through the ﬁlter. Filter segments generated by each participant
were composited in amber glass jars as daily samples and stored
frozen prior to analysis (shipped at ambient temperature). Butts
or ﬁlter segments were not analyzed if they were from an incorrect
brand or were damaged, i.e., burnt, excessively crushed or
extinguished in liquid.
Yield-in-use (YIU): YIU provides a non-invasive means to esti-
mate the amount of smoke that passes through the ﬁlter of a ciga-
rette and into the mouth of a smoker, i.e., mouth-level exposure
(MLE) (Nelson et al., 2011). To measure YIU, smoked cigarette butt
ﬁlter segments were extracted in methanol and the extracts ana-
lyzed by standardized methods (Labstat International ULC, Kitch-
ener, ON) to determine the amount of ‘‘tar’’ (colorimetric) and
nicotine (GC) trapped by the ﬁlter. The ‘‘tar’’ and nicotine quanti-
ﬁed are correlated to the amount of smoke passing through the ﬁl-
ter, as determined on a cigarette brand-speciﬁc basis by calibration
curves derived from machine-smoked cigarettes using ﬁve smok-
ing regimes of differing intensity, and results in an estimate of
maximum MLE. Comparisons between daily cigarette usage, butt
length and MLE were used to determine smoking behavior
between groups at baseline and whether changes were observed
during intervention in the Dual use group.2.5. Whole blood, plasma, urine and feces specimen collections
It is noted that while certain samples and analytes noted below
were collected and analyzed more frequently than reported herein,
for brevity, results are limited to D -1 and D5, and 22:00 hsampling periods, representing the greatest analyte concentration
changes observed.
Whole blood: Whole blood (EDTA) samples were collected on
days D -1, D 1, D 3, and D 5 at approximately 22:00 each day to
quantify carboxyhemoglobin concentrations spectroscopically
with a CO oximeter at Covance Central Clinical Laboratory (India-
napolis, IN). Samples were kept chilled prior to analysis.
Plasma: Plasma (sodium heparin) samples were collected on
days D -1, D 1, D 3, and D 5 at approximately 07:00, 12:00, and
22:00 each day to quantify nicotine and cotinine concentrations,
and at 22:00 to quantify thiocyanate concentrations. Plasma sam-
ples were stored frozen at 20 or 70 C prior to analysis.
Urine: 24-Hour urine samples were collected on days D -1, D 1,
D 3, and D5 following the collection procedure where the morn-
ing’s ﬁrst void was discarded and all subsequent voids collected
to include the ﬁrst void from the following morning. Samples were
stored refrigerated during collection, total daily (24-h) urine vol-
umes recorded, and bioanalytical aliquots stored frozen at 20 or
70 C prior to analysis. Feces: 24-Hour feces samples were col-
lected from up to six participants per group on days D -1 and D5
using a stool collection hat where daily composited samples were
collected throughout the collection day. Daily samples were
weighed and combined with deionized water (2:1, w:v), homoge-
nized using a probe-type homogenizer, and subsampled (20 g/
subsample) adding 1 g sodium azide/subsample as preservative.
Feces homogenate samples were stored frozen at 20 or 70 C
prior to analysis.
2.6. Urine mutagenicity
24-Hour urine mutagenicity (total revertants/day) was deter-
mined using a microsuspension-modiﬁed Ames test using Salmo-
nella typhimurium strain YG1024 with 5% Aroclor induced S9
(MolTox™; Molecular Toxicology Incorporated, USA) from male
Sprague Dawley rats. Strain YG1024 is an O-acetyltransferase-over
producing derivative of TA98 that is known to be more sensitive in
detecting mutagenicity in human urine caused by cigarette smok-
ing than TA98 (Kuenemann-Migeot et al., 1997). A 250-mL aliquot
of ﬁltered and pH neutralized 24-h urine sample was passed
through a Varian Megabond Elute C18 column (2 g C18 sorbent)
pre-conditioned by 2  5 mL each of methanol and then water.
The loaded column was washed with 2  5 mL water, and urinary
hydrophobic components eluted with 2  5 mL methanol/acetoni-
trile (1:1, v/v). Eluate was evaporated to dryness at 46 C under
nitrogen and resuspended in 500 lL DMSO. Resuspended solutions
were stored frozen at 80 C until assayed, and diluted with DMSO
to appropriate dose levels.
2.7. Biomarker analysis
Urinary and fecal biomarkers: All biomarker analyses were per-
formed by the bioanalytical laboratory (ABF GmbH, Munich, Ger-
many). Total daily excretion values presented for the urinary and
fecal analytes were calculated by converting analytically deter-
mined values to units of original concentration (i.e., biomarker
mass/mL urine or g feces), and multiplying the observed concen-
tration by total daily output (total mL urine or g feces/24-h) to
yield total excreted biomarker mass/day.
Total nicotine equivalents (T-NicEq) concentrations (comprised
of nicotine plus nine metabolites) were determined in urine and
feces homogenates by the same analytical methods; liquid chro-
matography—tandem mass spectroscopy (LC–MS/MS) according
to Meger et al. (2002), with major modiﬁcations. The analysis
was performed as two separate methods: (i) Nic + 5 (nicotine, coti-
nine, trans-30-hydroxycotinine, nicotine-glucuronide, cotinine-N-
glucuronide, trans-30-hydroxycotinine-N,O-glucuronide); and (ii)
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N-oxide, cotinine-N-oxide). Total daily T-NicEq excreted was
calculated by ﬁrst transforming the observed daily analyte concen-
trations (total mass/day) for each of the ten analytes to their
respective molar nicotine equivalent (NE) values (mass NE/day),
and then summing all NE values to yield total mass NE/day
(T-NicEq). The lower limits of quantitation (LLOQ) for all ten ana-
lytes ranged between 1.5 and 25 ng/mL in urine, and between 4
and 10 ng/g in feces.
Total tobacco-speciﬁc nitrosamine (TSNA) concentrations were
determined by liquid chromatography—tandem electrospray ioni-
zation (ESI) mass spectroscopy (LC–MS/MS) according to
Kavvadias et al. (2009). Samples were enzymatically hydrolyzed
with b-glucuronidase (type IX-A from Escherichia coli) prior to
analysis of four analytes: 4-methyl-N-nitrosamino-1-(3-pyridyl)-
1-butanol (total NNAL) [a metabolite of 4-methyl-N-nitrosamino-
1-(3-pyridyl)-1-butanone (NNK)], N-nitrosonornicotine (total
NNN), N-nitrosoanatabine (total NAT), and N-nitrosoanabasine
(total NAB). The LLOQ for all four analytes was 2 pg/mL.
Aromatic amine (AA) concentrations were determined by gas
chromatography/mass spectroscopy (GC/MS) in negative ion
chemical ionization (NICI) mode according to Riedel et al. (2006).
Samples were derivatized prior to analysis of four analytes: 3-ami-
nobiphenyl (3-ABP); 4-aminobiphenyl (4-ABP); 2-amino naphtha-
lene (2-AN); and o-toluidine (o-T). The LLOQ for all four analytes
ranged between 1.0 and 2.5 pg/mL.
Hydroxylated polyaromatic hydrocarbon (PAH) concentrations
were determined by gas chromatography–mass spectroscopy,
selected reaction monitoring (SRM) mode (GC–MS/MS) with mod-
iﬁed methods of Chetiyanukornkul et al. (2006). Samples were
enzymatically hydrolyzed with b-glucuronidase/arylsulfatase
(from Helix pomatia) and derivatized prior to analysis of nine
analytes: 1-OH-pyrene, 1- and 2-OH-naphthalene, 2 OH-ﬂourene,
1-, 2-, 3-, 4-, and 9-OH-phenanthrene. The LLOQ for all nine
analytes ranged between 0.01 and 1.00 ng/mL.
3-Hydroxypropylmercapturic acid (HPMA), ametabolite of acro-
lein had concentrations determined by liquid chromatography—
tandem electrospray ionization (ESI, negative) mass spectroscopy
(LC–MS/MS) according to Mascher et al. (2001). N-acetyl-S-(2-
hydroxy-2-carbamoylethyl)cysteine (GAMA) andN-acetyl-S-(2 car-
bamoylethyl)cysteine (AAMA), metabolites of acrylamide, had con-
centrations determined by liquid chromatography—tandem
electrospray ionization (ESI, negative) mass spectroscopy (LC–MS/
MS) according to Urban et al. (2006). The LLOQ for HPMA, GAMA
and AAMA were 20, 1.0 and 4.1 ng/mL, respectively. S-phenylmer-
capturic acid (SPMA), a metabolite of benzene, had concentrations
determined by liquid chromatography—tandem atmospheric pres-
sure chemical ionization (negative mode) (APCI, negative) mass
spectroscopy (LC–MS/MS) by a modiﬁed method of Paci et al.
(2007) that includes hydrochloric acid hydrolysis of urine to convert
pre-SPMA to SPMA (Sterz et al., 2010). The LLOQ for SPMA was
0.05 ng/mL. Monohydroxybutenyl-mercapturic acids (MHBMA)
and dihydroxy-butylmercapturic acid (DHBMA), metabolites of
1,3-butadiene had concentrations determined by liquid chromatog-
raphy—tandem electrospray ionization (ESI, negative) mass spec-
troscopy (LC–MS/MS) according to Urban et al. (2003). The LLOQ
for MHBMA and DHBMA were 0.5 and 4.4 ng/mL, respectively. 2-
Hydroxyethylmercapturic acid (HEMA), a metabolite of ethylene
oxide, and 2-cyanoethylmercapturic acid (CEMA), a metabolite of
acrylonitrile had concentrations determinedby liquid chromatogra-
phy—tandem electrospray ionization (ESI, positive) mass spectros-
copy (LC–MS/MS) according to Scherer et al. (2010). Thiocyanate
urinary concentrations were determined by a GC–MS method
according to Riedel et al. (2013), with a LLOQ of 0.7 lmol/L.
Plasma biomarkers: Nicotine and cotinine plasma concentra-
tions were determined by liquid chromatography—tandem massspectroscopy (LC–MS/MS) after protein precipitation according to
a validated method by the analytical laboratory (ABF GmbH,
Munich, Germany). The LLOQ for both analytes was 1.0 ng/mL.
Thiocyanate plasma concentrations were determined according
to Degiampietro et al. (2009). Absorption was measured with a
SLT Spectra multi-channel-reader (Tecan GmbH, Crail, Germany)
at 492 nm, using a 620 nm reference ﬁlter. The LLOQ for thiocya-
nate was 0.7 lmol/L.
2.8. Questionnaire administration
MNWS-R: The self-reported Minnesota Nicotine Withdrawal
Scales-Revised (MNWS-R) questionnaire can be scored with 9-
Items or 15-Items, where the ﬁrst nine items are validated
(angry/irritable/frustrated, anxious/nervous, depressed mood/sad,
desire or craving to smoke, difﬁculty concentrating, increased
appetite/hungry/weight gain, insomnia/sleep problems/awakening
at night, restless, and impatient) and the remaining 6 items inves-
tigational, but seemingly relevant for evaluating DTPs (i.e., consti-
pation, dizziness, coughing, dreaming/nightmares, nausea, and
sore throat) (Hughs and Hatsukami, 2007). Participants rated each
item on a ﬁve point scale from 0 (none) to 4 (severe) in the eve-
nings on baseline day and Days 1, 3, and 5.
2.9. Statistical analysis
This trial was a ‘‘complete-case’’ trial, i.e., only data from partic-
ipants who successfully completed the trial were included in the
statistical analysis. The sample size of ‘completers’ was determined
based on a previous trial when participants switched from smoking
their UB to the use of a similar dissolvable tobacco product, to pro-
vide at least 80% statistical power to detect a 20% reduction in
NicEq-T and NNAL in 24-h urine at a 5% signiﬁcance level and
two-sided testing. All participants receiving test products were
included in the reporting of demographics and adverse events.
All statistical analyses were done using SAS and statistical signiﬁ-
cance was considered at p 6 0.05.
Categorical and continuous variables were summarized by ran-
domization group and, where relevant, by sampling time. Summa-
ries of categorical variables included counts and percentages per
applicable category. Descriptive statistics for continuous variables
included the number of non-missing values, mean, geometric
mean, standard deviation (SD), median, minimum, and maximum.
Summaries of biomarker data also included percent change of
mean from baseline, which was deﬁned as the values from Day -
1. One-way Analysis of variance (ANOVA) model was used to per-
form baseline comparisons among appropriate groups for end-
points related to ‘product use’ including UB cigarette
dispensation, butt length, YIU (‘tar’ and nicotine MLE), and Snus-
After-Use (nicotine MLE). The p-values for pairwise comparison
between any two groups were derived. Within each of ﬁve product
groups, t-test was used to assess the signiﬁcance of the changes
from baseline (deﬁned as Day 1) to Day 5 and regression analysis
was performed to assess the product usage trend over time, where
day was treated as a continuous variable.
For biomarker data, analytical values above the limit of detec-
tion (LOD) will be reported unchanged. Values below the LOD were
reported as ½ the LOD. For blood level %COHb measurements, if
%saturation is below the level of quantiﬁcation, the value was
replaced by 0.15%. Missing data were not imputed or replaced by
any value. ANOVA models were used to compare baseline bio-
marker level across groups as well as to compare product effect
on the absolute changes from baseline to Day 5 for biomarkers in
all categories. Multiple comparisons of all pairwise groups were
performed. For endpoints which were collected on more than
2 days, variable ‘‘day’’ and the interaction between product group
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ison of groups was performed on each day. Paired t-test was used
to assess the signiﬁcance of the changes from baseline to Day 5 for
each group.
For all questionnaire measures, when data were available,
descriptive statistics were calculated by group and time points.
Statistical analysis was performed for the FTND and MNWS ques-
tionnaires by scoring according to published algorithms. Observed
as well as adjusted mean change in scale scores from baseline were
reported for the MNWS by randomized group and assessment per-
iod (Day 1, 3, and 5). The adjustment was carried out by modeling
observed change from Baseline scale scores as a function of ran-
domization group, subject, and assessment period, adjusting for
Baseline scale scores using analysis of covariance (ANCOVA)model.
The 95% conﬁdence interval of the least square mean of change
scores was obtained. Differences in adjusted scale change scores
were examined for all paired randomization groups and the p-val-
ues were obtained. For FTND data, one-way ANOVA model was
built for pairwise comparisons between randomization groups.3. Results
A total of 181 participants were enrolled, randomized and at a
minimum started their intervention. Of these, 167 participants
completed the trial: two withdrew due to an adverse event (AE),
both considered not product related; 11 withdrew consent; and
one withdrew for personal reasons. Numbers of participants with
chronic health conditions controlled by daily use of prescription
or OTC medications were generally evenly distributed between
groups. Of the overall number of participants (167), 29 were trea-
ted with a single medication, whereas 19 had multiple medica-
tions. Medications were taken to treat: hypertension (15);
chronic pain (12); depression/anxiety/ADD (9); hormones for birth
control or transgender (7); cardiac prophylaxis (6); hypercholes-
terolemia (5); chronic headache (5); insomnia (4); allergies (3);Table 1
Participant demographic characteristics at time of screening.
Demographic variable Dual use N = 29 SNUS N = 30 Sticks N = 29
Age (years)
Mean ± SD 42.45 ± 12.28 37.60 ± 11.42 40.72 ± 12.22
(Min–max) 23–63 21–59 24–64
Weight (kg)
Mean ± SD 81.66 ± 22.49 79.82 ± 15.50 79.51 ± 14.84
(Min–max) 51.9–146.0 55.4–118.2 49.2–114.5
Height (cm)
Mean ± SD 168.20 ± 7.63 172.02 ± 7.82 172.44 ± 8.46
(Min–max) 156.0–182.8 158.5–184.2 156.7–189.5
BMI (kg/m2)
Mean ± SD 28.76 ± 7.12 27.14 ± 5.99 26.77 ± 4.97
(Min–max) 19.2–46.0 19.9–43.6 18.3–44.2
Gender (n [%])
Male 14 (48.3) 18 (60.0) 17 (58.6)
Female 15 (51.7) 12 (40.0) 12 (41.4)
Ethnicity (n [%])
Hispanic or Latino 3 (10.3) – 1 (3.4)
Not Hispanic or Latino 26 (89.7) 30 (100) 28 (96.6)
Race (n [%])
White 25 (86.2) 23 (76.7) 21 (72.4)
Black or African 4 (13.8) 6 (20.0) 6 (20.7)
American
Asian – – –
American – – 1 (3.4)
Indian/Alaskan native
Other – 1 (3.3) 1 (3.4)
Fagerström test score
Mean ± SD 5.52 ± 1.79 5.13 ± 1.46a 5.41 ± 1.40b
a Signiﬁcantly (p 6 0.05) lower compared to Strips and Abstinent groups.
b Signiﬁcantly (p 6 0.05) lower compared to Abstinent group.and type 2 diabetes (1). Besides medications, it is noted 16 partic-
ipants used health supplements daily, usually a multivitamin.
Demographic data at time of screening are presented in Table 1,
with attributes appearing relatively balanced although no formal
comparisons were made except for FTND. Groupmean FTND scores
ranged between 5.3 and 6.3 with some statistical differences noted
between groups, attributed to instrument (questionnaire) variabil-
ity. Of the 288 reported AEs, 282 were considered mild and 6 mod-
erate. 152 AEs were considered related to study products, most
commonly headache, nausea and ﬂatulence.
Daily smoking behavior measures of CPD, ‘tar’ and nicotine
MLEs, butt lengths, and daily test product usage rates are pre-
sented in Table 2. On baseline day, group mean smoking rates were
only signiﬁcantly different between the lowest Snus and highest
Strips groups. Not surprisingly, given the mandatory 60% baseline
CPD reduction, the Dual use group had a signiﬁcantly reduced
CPD at Day 5, where participants smoked the mean maximum
allowable rate (7.6 CPD) during all 5 days. No statistical differences
were observed between groups on baseline day for mean MLE to
‘tar’ (393–467 mg/day) or nicotine (32–39 mg/day). For the Dual
use group during the intervention period, daily MLE to ‘tar’ and
nicotine were both reduced to 50% of baseline levels. It is notable
that the daily MLE reductions observed occurred notwithstanding
the fact that when MLE is computed on a per cigarette basis,
MLE to ‘tar’ and nicotine increased by 27% and 28%, respectively.
Some slight but signiﬁcant differences were also noted between
group mean butt lengths on baseline day, which ranged between
35.0 and 37.3 mm. For the Dual use group during the intervention
period, butt lengths were slightly but signiﬁcantly shorter
(2.5 mm) on Day 5 compared to baseline. Overall, while minor
baseline differences in group comparisons for CPD and butt length
were observed, given no differences in daily MLE to ‘tar’ and nico-
tine between groups, the differences noted were not considered
meaningful. For the Dual use group during the intervention period,
increases in per cigarette ‘tar’ and nicotine MLEs and a decrease inStrips N = 25 Orbs N = 29 Abstinence N = 25 Total N = 167
40.64 ± 11.76 39.34 ± 12.71 43.32 ± 11.20 40.60 ± 11.93
22–63 21–63 21–58 21–64
77.09 ± 19.33 76.95 ± 17.22 79.02 ± 22.74 79.06 ± 18.60
44.7–119.0 48.3–107.6 54.2–151.9 44.7–151.9
172.48 ± 8.26 169.24 ± 7.93 173.17 ± 8.99 171.19 ± 8.26
152.1–183.8 154.7–186.1 149.1–189.5 149.1–189.5
25.87 ± 6.10 26.83 ± 5.83 26.18 ± 6.35 26.97 ± 6.07
17.6–40.9 18.4–40.2 18.6–48.3 17.6–48.3
14 (56.0) 13 (44.8) 14 (56.0) 90 (53.9)
11 (44.0) 16 (55.2) 11 (44.0) 77 (46.1)
4 (16.0) – 1 (4.0) 9 (5.4)
21 (84.0) 29 (100) 24 (96.0) 158 (94.6)
22 (88.0) 19 (65.5) 21 (84.0) 131 (78.4)
1 (4.0) 6 (20.7) 3 (12.0) 26 (15.6)
– 1 (3.4) – 1 (0.6)
– 1 (3.4) – 2 (1.2)
2 (8.0) 2 (6.9) 1 (4.0) 7 (4.2)
6.08 ± 1.38 5.28 ± 1.62b 6.32 ± 2.04 na
Table 2
Daily UB cigarette use rates and ‘tar’ and nicotine MLE, and smokeless product use rates.
Measure/intervention day Dual use Snus Sticks Strips Orbs Abstinent
Daily ‘‘n’’, M ± SD CPD⁄ smoked
Baseline 29 19.24 ± 7.40 30 16.33 ± 4.30b 29 18.48 ± 5.65 25 20.88 ± 5.82b 29 19.03 ± 4.32 25 19.44 ± 7.11
Day 1 29 7.62 ± 2.99 na na na na na
Day 2 29 7.62 ± 2.86 na na na na na
Day 3 29 7.55 ± 2.81 na na na na na
Day 4 29 7.55 ± 3.02 na na na na na
Day 5 29 7.62 ± 2.80a na na na na na
Daily ‘‘n’’, M ± SD ‘tar’ MLE (mg/day)
Baseline 29 415.3 ± 209.1 30 392.8 ± 178.1 29 406.8 ± 137.1 25 466.5 ± 194.4 29 400.4 ± 119.9 25 442.2 ± 187.9
Day 1 28 214.7 ± 209.1 na na na na na
Day 2 28 205.6 ± 105.1 na na na na na
Day 3 29 204.9 ± 100.3 na na na na na
Day 4 29 206.9 ± 106.0 na na na na na
Day 5 28 207.4 ± 107.1a na na na na na
Daily ‘‘n’’, M ± SD nicotine MLE (mg/day)
Baseline 29 34.26 ± 16.06 30 32.11 ± 17.98 29 33.00 ± 11.36 25 38.82 ± 17.51 29 32.13 ± 9.41 25 36.25 ± 15.42
Day 1 28 17.44 ± 8.63 na na na na na
Day 2 28 16.87 ± 8.10 na na na na na
Day 3 29 16.80 ± 7.23 na na na na na
Day 4 29 16.82 ± 7.95 na na na na na
Day 5 28 17.21 ± 7.89a na na na na na
Daily ‘‘n’’, M ± SD butt length (mm/butt)
Baseline 29 37.29 ± 2.52c 30 34.99 ± 4.99c,d 29 35.79 ± 4.08 25 36.22 ± 3.72 29 35.44 ± 4.38 25 37.18 ± 3.66c,d
Day 1 28 35.06 ± 3.14 na na na na na
Day 2 28 34.75 ± 3.47 na na na na na
Day 3 29 34.35 ± 4.44 na na na na na
Day 4 29 35.11 ± 3.66 na na na na na
Day 5 28 34.75 ± 3.53a na na na na na
Daily ‘‘n’’, M ± SD # units consumed
Baseline na na na na na na
Day 1 29 3.62 ± 1.32 30 6.10 ± 2.02 29 5.33 ± 2.69 25 12.04 ± 7.75 29 7.52 ± 24.11 na
Day 2 27 2.81 ± 1.36 28 5.71 ± 2.00 28 6.01 ± 4.20 24 13.67 ± 8.10 29 7.72 ± 5.02 na
Day 3 27 3.44 ± 1.58 30 6.27 ± 2.29 29 6.41 ± 3.99 25 15.16 ± 8.86 29 9.55 ± 6.37 na
Day 4 23 3.00 ± 1.76 28 5.82 ± 2.87 26 6.09 ± 4.02 22 14.18 ± 8.48 26 9.46 ± 6.59 na
Day 5 27 3.26 ± 1.97 30 6.43 ± 2.96 29 6.39 ± 4.44 25 13.48 ± 9.03 29 8.93 ± 5.57 na
* CPD = cigarettes per day.
 MLE = mouth level exposure from cigarette smoking.
a Statistically (p 6 .05) lower at Day 5 compared to baseline.
b Statistically (p 6 .05) different between Snus and Strips groups.
c Statistically (p 6 .05) different between Snus and Dual use groups.
d Statistically (p 6 .05) different between Snus and Abstinent groups.
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greater intensity compared to baseline.
Daily use rates of all the smokeless test products were uniform
throughout the intervention period, with no statistical differences
(Table 2). Of note was the use of 6 pouches/day in the exclusive
Snus group compared to about half that amount (3 pouches/
day) in the Dual use group.
Biomarker of exposure concentrations and relative percent
changes on Day 5 compared to baseline observed in urine, blood,
and plasma samples are provided in Table 3. Group biomarker per-
cent changes relative to the Abstinent group, whose biomarker
changes from baseline to Day 5 are considered to be 100% of
the maximum potential change possible, are depicted in Fig. 1
for T-NicEq, TSNAs and other select biomarkers, in Fig. 2 for AAs
and PAHs, and in Fig. 3 for select vapor phase biomarkers. For uri-
nary biomarkers, T-NicEq levels excreted at baseline were not sta-
tistically different (NSD) between groups, while on Day 5
signiﬁcant reductions were seen in all groups compared to base-
line, with Dual use having the least and the Abstinent group the
greatest decline, with intermediate declines in the remaining
groups. Day 5 group comparisons showed the Abstinent group
had a statistically greater reduction compared to all the other
groups, and the Strips, Orbs, and Abstinent groups had statisticallygreater reductions compared to Dual use. Relative to the Abstinent
group, reductions in the other groups ranged between 33% and
75% (Fig. 1).
Total TSNA levels excreted at baseline were NSD between
groups, while on Day 5 signiﬁcant reductions were seen in all
groups compared to baseline, with Dual use having the least and
the Abstinent group the greatest decline. Day 5 group comparisons
showed the Abstinent group had a statistically greater reduction
compared to all the other groups. Relative to the Abstinent group,
reductions in the other groups ranged between 28% and 47%
(Fig. 1). While levels of the four individual TSNAs excreted were
generally similar to the total TSNA ﬁndings, some exceptions were
noted. Total NNAL levels on Day 5 were signiﬁcantly reduced from
baseline only in the Dual use and Abstinent groups, whereas reduc-
tions were nominal in the Sticks (1%) and Snus (17%) groups,
with nominal increases seen in the Strips (9%) and Orbs (3%)
groups, all NSD from baseline. These ﬁndings may be related to
observations that NNK is converted to total NNAL to a greater
extent (3- to 4-fold) in consumers of smokeless tobacco com-
pared to cigarette smokers (Hecht et al., 2008; Stepanov et al.,
2008). Lastly, while most group comparisons at baseline for the
individual and total TSNAs were NSD, there was one exception;
the total NNN level was signiﬁcantly greater in the Snus group
Table 3
Biomarker of exposure concentrations in 24-h urine, whole blood, or plasma, and percent changes on Day 5 compared to baseline.
Group Total nicotine equivalents (mg/24-h Urine) Total TSNAs (ng/24-h Urine) Total NNAL (ng/24-h Urine)
Baseline Day 5 % Change Baseline Day 5 % Change Baseline Day 5 % Change
Dual use 22.59 ± 9.70 15.40 ± 7.17 31.8%a,b 1222.20 ± 540.79 907.90 ± 477.59 25.7%a,b 717.73 ± 326.22 572.90 ± 304.62 20.2%a,b
Snus 21.46 ± 7.49 11.25 ± 9.83 47.6%a,b 1115.05 ± 503.76 712.32 ± 588.06 36.1%a,b 596.37 ± 282.61 496.67 ± 330.54 16.7%a
Sticks 21.21 ± 7.42 11.08 ± 8.61 47.8%a,b 1148.44 ± 568.84 780.02 ± 517.13 32.1%a,b 598.44 ± 300.04 594.30 ± 360.60 0.7%a
Strips 22.48 ± 6.57 9.45 ± 5.98 58.0%a,b,d 1208.17 ± 562.17 946.40 ± 568.66 21.7%a,b 663.77 ± 336.83 725.59 ± 408.01 9.3%a,d
Orbs 21.18 ± 6.58 5.71 ±4.55 73.0%a,b,d 1250.65 ± 585.14 814.47 ± 547.28 34.9%a,b 677.69 ± 303.52 700.11 ± 454.35 3.3%a,d
Abstinent 22.89 ± 9.53 0.56 ± 0.47 97.6% b,d 1217.17 ± 548.40 272.86 ± 148.44 77.6%b,d 672.00 ± 299.84 267.89 ± 146.77 60.1%b,d
Total NNN (ng/24-h Urine) Total NAB (ng/24-h Urine) Total NAT (ng/24-h Urine)
Dual use 24.08 ± 21.93* 28.43 ± 41.40 18.1%a 68.30 ± 35.44 42.57 ± 26.88 37.7%a,b 412.92 ± 238.52 264.00 ± 184.62 36.1%a,b
Snus 42.70 ± 69.46* 22.62 ± 50.55 47.0%b,d 68.26 ± 37.74 29.73 ± 41.51 56.4%a,b 407.72 ± 250.76 163.30 ± 252.32 59.9%a,b
Sticks 27.71 ± 19.94 7.98 ± 7.44 71.2%b 74.48 ± 45.07 14.42 ± 13.11 80.6%b,d 447.81 ± 299.20 163.32 ± 180.74 63.5%a,b,d
Strips 26.90 ± 26.10 10.91 ± 16.55 59.5% b 71.77 ± 37.08 15.59 ± 13.88 78.3%b,d 445.73 ± 261.64 194.31 ± 190.48 56.4%a,b
Orbs 29.66 ± 17.88 9.34 ± 17.37 68.5%b,d 76.90 ± 39.14 9.24 ± 8.54 88.0%b,d 467.42 ± 264.52 95.77 ± 95.17 79.5%a,b,d
Abstinent 28.29 ± 19.77 1.79 ± 2.06 93.7%b,d 74.85 ± 43.16 1.25 ± 0.87 98.3%b,d 442.03 ± 236.39 1.93 ± 2.29 99.6%b,d
COHb (% Saturation in Whole Blood) Thiocyanate (lmol/24-h Urine) Thiocyanate (lmol/L Plasma)
Dual use 5.58 ± 2.27 2.90 ± 0.90 48.1%a,b 201.49 ± 100.07 157.65 ± 79.35 21.8%b 126.76 ± 45.11 99.78 ± 32.21 21.3%a,b
Snus 5.24 ± 1.62 0.98 ± 0.27 81.3%b,d 224.24 ± 122.60 119.29 ± 46.74 46.8%b,d 121.12 ± 39.48 80.55 ± 26.74 33.5%b,d
Sticks 5.23 ± 1.89 0.98 ±0.46 81.3%b,d 200.22 ± 124.40 108.49 ± 57.15 45.8%b,d 109.34 ± 36.43* 69.66 ± 21.66 36.3%b,d
Strips 6.16 ± 2.22 1.07 ± 0.31 82.7%b,d 246.58 ± 130.32 138.12 ± 68.36 44.0%b,d 138.17 ± 52.49* 84.50 ± 24.94 38.8%b,d
Orbs 5.82 ± 1.54 1.02 ± 0.30 82.5%b,d 203.56 ± 101.39 120.86 ± 58.45 40.6%b 120.11 ± 40.16 80.75 ± 26.56 32.8%b,d
Abstinent 6.19 ± 2.55 1.08 ± 0.22 82.5%b,d 222.38 ± 144.84 135.91 ± 92.48 38.9%b 122.36 ± 51.37 79.50 ± 28.04 35.0%b,d
YG1024 Mutagenicity (Revertants/103/24-h Urine) 3-Aminobiphenyl (ng/24-h Urine) 4-Aminobiphenyl (ng/24-h Urine)
Dual use 172.62 ± 118.10 100.44 ± 61.22 41.8%a,b 11.75 ± 6.34 6.46 ± 3.88 45.0%a,b 26.42 ± 11.39 14.64 ± 6.24 44.6%a,b
Snus 164.51 ± 85.17 49.74 ± 81.45 69.8%b 12.22 ± 5.49 1.41 ± 0.75 88.5%b,d 26.09 ± 11.36 3.74 ± 1.41 85.6%b,d
Sticks 191.86 ± 155.48 37.46 ± 41.53 80.5%b,d 11.42 ± 5.05* 1.02 ± 0.73 91.0%b,d 26.14 ± 9.35 3.64 ± 1.25 86.1%b,d
Strips 184.74 ± 110.68 27.86 ± 38.36 84.9%b,d 14.85 ± 7.73* 1.47 ± 0.97 90.1%b,d 27.03 ± 9.53 4.10 ± 1.74 84.8%b,d
Orbs 199.66 ± 105.00 24.67 ± 21.72 87.6%b,d 12.67 ± 5.57 1.14 ± 0.68 91.0%b,d 29.49 ± 12.33 3.86 ± 1.43 86.9%b,d
Abstinent 187.78 ± 107.49 34.36 ± 43.41 81.7%b,d 14.10 ± 6.15 1.33 ± 0.87 90.6%b,d 27.44 ± 10.79 4.31 ± 1.67 84.3%b,d
2-Aminonaphthalene (ng/24-h Urine) o-Toluidine (ng/24-h Urine) 1-OH-Pyrene (ng/24-h Urine)
Dual use 37.92 ± 17.13 20.35 ± 9.27 46.3%a,b 228.39 ± 86.02* 159.04 ± 62.47 30.4%a,b 392.62 ± 173.07 404.56 ± 386.46 3.0%nsd
Snus 37.65 ± 14.77 3.28 ± 1.43 91.3%b,d 223.18 ± 75.07* 89.82 ± 36.41 59.8%b,d 410.85 ± 172.96 377.07 ± 520.67 8.2%nsd
Sticks 36.28 ± 13.09 3.07 ± 1.28 91.5%b,d 241.05 ± 88.97 88.47 ± 27.95 63.3%b,d 350.76 ± 149.21 372.23 ± 527.22 6.1%nsd
Strips 40.38 ± 16.66 3.64 ± 1.22 91.0%b,d 275.86 ±99.88* 117.41 ± 46.99 57.4%b,d 428.60 ± 293.91 359.90 ± 485.29 16.0%nsd
Orbs 45.24 ± 35.02 3.39 ± 1.36 92.5%b,d 233.36 ± 58.47 101.04 ± 43.33 56.7%b,d 347.68 ± 103.30 355.26 ± 511.36 2.2%nsd
Abstinent 39.34 ± 16.97 3.53 ± 1.35 91.0%b,d 255.76 ± 84.22 102.82 ± 43.38 59.8%b,d 408.13 ± 218.78 241.13 ± 259.45 40.9%nsd
1-OH-Naphthalene (lg/24-h Urine) 2-OH-Naphthalene (lg/24-h Urine) 2-OH-Flourene (ng/24-h Urine)
Dual use 12.08 ± 5.72 7.60 ± 3.68 37.1%a,b 17.75 ± 7.24 11.33 ± 5.27 36.2%a,b 2048.77 ± 813.21 1406.72 ± 565.19 31.3%a,b
Snus 12.80 ± 5.95 2.59 ± 4.03 79.7%b,d 18.76 ± 6.63 4.08 ± 3.08 78.2%b,d 2166.66 ± 780.94 574.39 ± 217.58 73.5%b,d
Sticks 11.72 ± 4.46 2.95 ± 4.42 74.8%b,d 17.91 ± 5.52 3.62 ± 2.73 79.8%b,d 2039.09 ± 612.29 561.52 ± 196.04 72.5%b,d
Strips 13.73 ± 5.39 2.42 ± 3.24 82.4%b,d 18.93 ± 5.90 3.48 ± 1.36 81.6%b,d 2261.26 ± 804.78 610.34 ± 236.88 73.0%b,d
Orbs 12.38 ± 4.51 1.69 ± 1.63 86.4%b,d 17.77 ± 5.03 4.65 ± 4.04 73.8%b,d 2094.01 ± 607.56 613.78 ± 362.33 70.7%b,d
Abstinent 12.60 ± 6.29 2.60 ± 4.59 79.4%b,d 18.01 ± 6.22 3.30 ± 1.69 81.7%b,d 2141.86 ± 860.33 597.85 ± 260.32 72.1%b,d
1-OH-Phenanthrene (ng/24-h Urine) 2-OH-Phenanthrene (ng/24-h Urine) 3-OH-Phenanthrene (ng/24-h Urine)
Dual use 263.02 ± 88.87 204.90 ± 63.79 22.1% a,b 149.49 ± 48.21 120.28 ± 38.69 19.5% a,b 316.06 ± 102.81 242.37 ± 85.47 23.3% a,b
Snus 284.52 ± 91.67 139.17 ± 62.90 51.1% b,d 153.17 ± 59.28 80.57 ± 54.85 47.4% b,d 332.80 ± 94.68 129.17 ± 73.03 61.2% b,d
Sticks 261.98 ± 72.10 142.95 ± 79.11 45.4% b,d 158.64 ± ± 92.57 94.37 ± 57.32 40.5% b,d 305.62 ± 114.22 141.38 ± 90.96 53.7% b,d
Strips 286.42 ± 93.60 152.58 ± 70.78 46.7% b,d 165.00 ± 61.05 85.52 ± 51.18 48.2% b,d 351.35 ± 124.71 148.06 ± 94.20 57.9% b,d
Orbs 283.99 ± 74.59 151.91 ± 64.04 46.5% b,d 152.50 ± 51.45 93.21 ± 53.12 38.9% b 340.48 ± 98.67 145.65 ± 84.79 57.2% b,d

















4-OH-Phenanthrene (ng/24-h Urine) 9-OH-Phenanthrene (ng/24-h Urine) CEMA (lg/24-h Urine)
Dual use 65.91 ± 25.71 49.71 ± 18.43 24.6%a,b 270.68 ± 140.19 194.75 ± 85.07 28.1%a,b 274.56 ± 137.25 150.79 ± 74.27 45.1%a,b
Snus 69.69 ± 24.21 25.48 ± 17.12 63.4%b,d 289.94 ± 116.74 71.71 ± 64.85 75.3%b,d 278.63 ± 122.74 37.69 ± 17.42 86.5%b,d
Sticks 68.45 ± 28.02 27.23 ± 17.65 60.2%b,d 279.72 ± 115.51 80.51 ± 68.16 71.2%b,d 262.50 ± 92.15 40.83 ± 18.78 84.4%b,d
Strips 75.27 ± 27.23 30.33 ± 21.51 59.7%b,d 306.75 ± 126.81 83.83 ± 50.28 72.7%b,d 322.98 ± 147.2 45.99 ± 20.62 85.8%b,d
Orbs 76.92 ± 27.10 30.43 ± 22.62 60.4%b,d 311.35 ± 121.88 87.38 ± 87.79 71.9%b,d 262.73 ± 85.55 33.03 ± 13.12 87.4%b,d
Abstinent 75.48 ± 35.44 23.08 ± 16.83 69.4%b,d 317.14 ± 155.69 68.33 ± 37.21 78.5%b,d 287.24 ± 117.63 40.99 ± 22.94 85.7%b,d
HEMA (lg/24-h Urine) HPMA (lg/24-h Urine) AAMA (lg/24-h Urine)
Dual use 12.33 ± 6.91 8.73 ± 5.50 29.2%a,b 2820.28 ± 1352.86 1415.78 ± 558.73 49.8%a,b 359.58 ± 115.27* 265.04 ± 95.57 26.3%a,b
Snus 16.07 ± 8.40* 6.73 ± 2.99 58.1%b,d 2678.81 ± 978.80 445.39 ± 288.51 83.4%b,d 428.89 ± 140.62* 152.92 ± 73.80 64.3%b,d
Sticks 11.64 ± 4.87* 7.19 ± 4.03 38.2%b,d 2607.31 ± 1012.32 470.06 ± 174.55 82.0%b,d 395.63 ± 149.36 146.73 ± 54.85 62.9%b,d
Strips 12.40 ± 6.78 6.48 ± 3.87 47.7%b,d 3113.38 ± 1268.96 466.45 ± 180.00 85.0%b,d 407.21 ± 140.53 135.55 ± 28.14 66.7%b,d
Orbs 13.06 ± 7.07 7.62 ± 3.89 41.7%b,d 2696.71 ± 866.21 452.57 ± 217.75 83.2%b,d 374.78 ± 110.44 146.92 ± 55.08 60.8%b,d
Abstinent 15.64 ± 12.86 7.27 ± 4.49 53.5%b,d 2865.21 ± 1210.80 473.70 ± 212.59 83.5%b,d 405.57 ± 124.00 146.11 ± 37.85 64.0%b,d
GAMA (lg/24-h Urine) HMPMA (lg/24-h Urine) MHBMA (ng/24-h Urine)
Dual use 49.79 ± 20.00 39.18 ± 15.33 21.3%a,b 642.88 ± 287.21 363.11 ± 164.18 43.5%a,b 7688.81 ± 4716.43 3833.51 ± 2285.38 50.1%a,b
Snus 57.31 ± 22.00 27.64 ± 10.53 51.8%b,d 617.87 ± 242.53 125.78 ± 57.97 79.6%b,d 8911.75 ± 5896.10 707.07 ± 247.61 92.1%b,d
Sticks 52.00 ± 18.74 27.41 ± 11.25 47.3%b,d 599.68 ± 239.58 139.07 ± 77.14 76.8%b,d 6186.13 ± 4700.37* 753.70 ± 315.36 87.8%a,b
Strips 45.47 ± 16.79 22.44 ± 5.72 50.6%b,d 687.95 ± 304.11 130.63 ± 63.32 81.0%b,d 6688.63 ± 4592.95* 664.74 ± 325.73 90.1%a,b
Orbs 47.32 ± 18.66 25.62 ± 9.17 45.9%b,d 600.96 ± 233.99 117.34 ± 56.34 80.5%b,d 9092.82 ± 5563.85 670.29 ± 286.10 92.6%b,d
Abstinent 49.06 ± 20.82 24.81 ± 7.72 49.4%b,d 614.94 ± 231.47 125.49 ± 62.93 79.6%b,d 10702.67 ± 8487.79* 738.32 ± 328.26 93.1%b,d
SPMA (ng/24-h Urine) Nicotine (ng/mL Plasma @ 22:00) Cotinine (ng/mL Plasma@ 22:00)
Dual use 6349.75 ± 4247.47 3411.91 ± 2350.75 46.3%a,b 28.43 ± 14.34 15.34 ± 6.84 46.0%a,b 300.63 ± 135.61 191.91 ± 103.83 36.2%a,b
Snus 6302.54 ± 3168.36 523.27 ± 301.82 91.7%b,d 27.25 ± 9.21 10.37 ± 9.18 61.9%a,b 296.65 ± 108.06 143.09 ± 126.69 51.8%a,b
Sticks 4784.78 ± 3046.34* 493.12 ± 263.16 89.7%b,d 25.9 ± 10.10 7.49 ± 5.27 71.1%a,b 280.60 ± 80.61 139.52 ± 104.09 50.3%a,b
Strips 5555.02 ± 3783.57 531.81 ± 260.01 90.4%b,d 31.48 ± 9.32 7.21 ± 4.68 77.1%b,d 321.59 ± 98.22 115.42 ± 67.90 64.1%a,b,d
Orbs 7059.41 ± 4057.39⁄ 543.05 ± 226.15 92.3%b,d 26.49 ± 7.39 3.98 ± 2.17 85.0%a,b,d 306.53 ± 111.80 59.89 ± 37.76 80.5%a,b,d
Abstinent 7288.75 ± 4947.08* 612.93 ± 408.37 91.6%b,d 29.90 ± 14.91 0.78 ± 0.90 97.4%b,d 317.39 ± 149.40 3.85 ± 5.88 98.8%b,d
* Statistically (p 6 0.05) different for between group pair-wise comparisons at baseline.
nsd Not statistically different in either between group pair-wise, or within group baseline comparisons.
a Statistically (p 6 0.05) different compared to Abstinent group.
b Statistically (p 6 0.05) different compared to within group baseline comparison.

















Fig. 1. Select urinary, whole blood or plasma biomarker level percent changes relative to the Abstinent group at Day 5 compared to baseline.
Fig. 2. Aromatic amine and polyaromatic hydrocarbon urinary biomarker level percent changes relative to the Abstinent group at Day 5 compared to baseline.
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ally high mean ± SD variability observed in the Snus group.
Aromatic amine (AA) levels excreted at baseline were NSD
between all groups for 4-aminobiphenyl and 2-aminonaphthalene.
Signiﬁcant differences were observed for 3-aminobiphenyl
between the lowest Sticks and highest Strips groups, and for o-
toluidine between the two lowest Dual use and Snus groups and
highest Strips group. Group reductions for all four individual AAs
on Day 5 were substantial for the non-smoking Snus, Sticks, Strips,
Orbs, and Abstinent groups, and all groups had signiﬁcant reduc-
tions compared to baseline. Notably, the magnitude of Day 5
reductions for the four individual AAs in the non-smoking (Snus,
Sticks, Strips, and Orbs) groups were comparable to the Abstinent
group (ranging between 95% and 102% relative to Abstinent),
whereas the Dual use group reductions were consistently approx-
imately one-half (ranging between 50% and 53% relative toAbstinent; Fig. 2) of those seen in the non-smoking groups, with
all Day 5 Dual use AA comparisons between the non-smoking
groups being signiﬁcantly different.
Polyaromatic hydrocarbon (PAH) levels excreted at baseline
were NSD between all groups for all nine of the PAH biomarkers.
Similar to the AA ﬁndings, group reductions for eight of the indi-
vidual PAHs on Day 5 were substantial for the non-smoking groups
(ranging between 76% and 109% relative to Abstinent; Fig. 2),
and all groups had signiﬁcant reductions compared to baseline.
Dual use group reductions were approximately one-third to one-
half of those seen in the non-smoking groups (ranging between
35% and 47% relative to Abstinent), with all Dual use group
PAH comparisons between the non-smoking groups signiﬁcantly
different, except the 2-OH-phenanthrene Orbs group that was
NSD. Of exception to these ﬁndings was 1-OH-pyrene, which
showed only nominal changes on Day 5, ranging between 39%
Fig. 3. Select vapor phase urinary biomarker level percent changes relative to the Abstinent group at Day 5 compared to baseline.
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Day 5 group comparisons.
For the vapor phase biomarkers, levels excreted at baseline
were NSD in group comparisons for CEMA, HPMA, GAMA, and
HMPMA. Signiﬁcant differences were observed for HEMA between
the lowest Sticks and highest Snus groups, for AAMA between the
lowest Dual use and highest Snus groups, for MHBMA between the
two lowest Sticks and Strips groups and highest Abstinent group,
and for SPMA between the lowest Sticks and two highest Orbs
and Abstinent groups. Similar to the previous ﬁndings, group
reductions for all vapor phase biomarkers on Day 5 were substan-
tial for the non-smoking groups (ranging between 71% and
109% relative to Abstinent; Fig. 3), and all groups had signiﬁcant
reductions compared to baseline. Day 5 Dual use group reduction
levels were consistently approximately one-half of those seen in
the non-smoking groups, with all Dual use group comparisons
between the non-smoking groups being signiﬁcantly different.
Mutagenicity levels excreted at baseline ranged between
164,510 and 191,860 revertants/24-h urine, which were NSD
between all groups. Group reductions on Day 5 were substantial
for the non-smoking groups (ranging between 85% and 107%
relative to Abstinent; Fig. 1), and all groups had signiﬁcant reduc-
tions compared to baseline. Similar to the discrete chemical bio-
markers, the magnitude of Day 5 mutagenicity reductions were
comparable between the Abstinent and non-smoking groups,
whereas the Dual use group reduction was approximately one-half
(51% relative to Abstinent) of those seen in the non-smoking
groups, with all Day 5 Dual use group comparisons between the
non-smoking groups being signiﬁcantly different, except the Snus
group.
Evening (22:00) plasma nicotine and cotinine levels at base-
line were both NSD between all groups. Similar to the urinary
T-NicEq results, Day 5 reductions in both plasma nicotine and coti-
nine were observed in all groups, where the least was in the Dual
use and greatest in the Abstinent groups, while the magnitude of
reductions varied by test product, such that Orbs > Strips > -
Sticks = Snus. Day 5 Dual use reductions for nicotine and cotinine
were approximately one-half and one-third of those seen in the
Abstinent group, respectively. Evening blood COHb percent satura-
tion levels at baseline were all P5%, indicative of being an active
smoker, and were NSD between all groups. Expectedly, group
COHb reductions on Day 5 for the non-smoking groups were sub-
stantial (ranging between 96% and 99% relative to Abstinent;
Fig. 1), and all groups had signiﬁcant reductions compared tobaseline. The magnitude of Day 5 reductions were comparable
between the Abstinent and the non-smoking groups, whereas the
Dual use group reduction level was slightly greater than one-half
(57% relative to Abstinent) of those seen in the non-smoking
groups, with all Day 5 Dual use group comparisons between the
non-smoking groups being signiﬁcantly different.
Evening plasma thiocyanate levels at baseline were NSD in all
group comparisons, except for the lowest Sticks and highest Strips
groups. Also expectedly, group reductions on Day 5 for the non-
smoking groups were robust (ranging between 94% and 111%
relative to Abstinent), and all groups had signiﬁcant reductions
compared to baseline. The magnitude of Day 5 reductions were
comparable between the Abstinent and non-smoking groups,
whereas the Dual use group reduction level was slightly greater
than one-half (61% relative to Abstinent) of those seen in the
non-smoking groups, with all Day 5 Dual use group comparisons
between the non-smoking groups being signiﬁcantly different.
Thiocyanate levels were also quantiﬁed as lmol/24-h urine, and
ﬁndings were generally comparable with the plasma results
(Table 3).
Fecal T-NicEq levels excreted at baseline and Day 5 were quan-
tiﬁed in a small subset (3–5) of participants in each group (data not
shown). For all groups at both time points, fecal excretion was neg-
ligible relative to urinary excretion, with mean levels ranging
between 8 and 118 lg/24-h, and unlike urine, no conjugated
metabolites were detected. Notably, analytical intra- and inter-
group variability appeared excessive, attributed to urine cross-con-
tamination of the feces samples collected. Nevertheless, based on
T-NicEq masses recovered in both urine and feces, fecal excretion
accounted for only 62% of the total, a value similar to the 1% fecal
excretion level reported for smokers in a 14C-nicotine mass bal-
ance study (Armitage et al., 1975).
In the self-reported 15-Item-MNWS-R questionnaire, higher
scores connote a greater level of withdrawal discomfort. At base-
line, group mean ± SD scores ranged between 5.5 ± 6.0 and
9.1 ± 7.5, and were NSD between all groups, except for the lowest
Orbs and highest Strips groups, which were signiﬁcantly
(p 6 0.05) different. By Day 5 scores were lowest (6.5 ± 7.5) for Dual
use and highest (12.1 ± 11.7) for the Abstinent groups. All Day 5 to
baseline comparisons were NSD, with the exception of the Absti-
nent groupwhose score increased by 74%. Day 5 group comparisons
showed the Abstinent’s group score was signiﬁcantly greater than
the Dual use and Snus groups, but NSD between the Sticks, Strips
and Orbs groups. It is noted that the group comparison results from
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the 15-Item results, and are not reported.
4. Discussion
Methods used in this trial were adapted from a previous similar
trial (Krautter and Borgerding, 2014) that studied an earlier version
of Orbs for use patterns, toxicant exposure and subjective effects.
While beneﬁtting from good compliance inherent in a conﬁnement
trial, participants were allowed limited alcoholic beverages during
evening meals, a feature 77% of participants choose to use. Another
feature was use of a controlled diet, low in potentially confounding
biomarkers (i.e., PAHs, AAs, and cyanogens). Recognizing that some
smokers will Dual use cigarettes with various smokeless tobacco
products (STPs), a Dual use cohort was included that restricted
their CPD by 60% to standardize reduced smoking rates. Randomi-
zation of participants into the 6 groups was well balanced, given
that no statistical differences were observed at baseline between
groups for the primary clinical parameters of cigarette smoke
exposure, namely: blood COHb%, urinary T-NicEq and plasma nic-
otine and cotinine concentrations.
Results demonstrate that when active smokers switch to exclu-
sive use of Snus, Sticks, Strips, or Orbs, after 5 days their biomark-
ers of exposure to toxicants in cigarette smoke were substantially
and signiﬁcantly reduced, usually comparable in magnitude to
being tobacco abstinent. Similarly, when smoking rates are
reduced by 60% in Dual users, signiﬁcant but less robust toxicant
reductions are still evident. In a similar biomarker study of Dual
users of cigarettes and Snus, the authors suggest that Dual use does
not result in compensatory changes in the way each cigarette was
smoked, but do acknowledge the lack of data where a systematic
assessment of cigarette smoke exposure during Dual use is avail-
able (Sarkar et al., 2009). This trial did include such an assessment
and results indicate that MLE did increase on a per cigarette basis,
but when participants reduced their CPD by 60%, their daily ‘tar’
and nicotine MLE was reduced by 50%, indicating a net beneﬁt
in reduced toxicant exposures under these product use conditions.
Of the 32 biomarkers of exposure studied, there are two notable
biomarkers that yielded apparent anomalous results; 1-OH-pyrene
and NNAL. 1-OH-pyrene has long been used as a surrogate bio-
marker for occupational, environmental and dietary exposures to
PAHs. While pyrene is known to be present in cigarette smoke, it
has no known toxicological consequences. Perhaps a better bio-
marker of exposure for PAHs from cigarette smoke or smokeless
tobacco is benzo(a)pyrene (BaP), by quantifying one of its urinary
metabolites, 3-OH-BaP. During planning of this trial, methods for
urinary BaP were not widely available and we elected to use a
PAH panel of nine metabolites, including 1-OH-pyrene. Eight PAH
metabolites showed consistent and substantial PAH reductions
on Day 5 for all the non-smoking groups, whereas changes in 1-
OH-pyrene were NSD on Day 5 between all groups and baseline
comparisons. Variability in 1-OH-pyrene urinary excretion and its
poor correlation with nicotine smoke exposure have been noted
by others (Hecht et al., 2004; St. Helen et al., 2012; USDHHS,
2010). The lack of 1-OH-pyrene reductions noted in this trial again
suggests it is not a reliable biomarker in tobacco studies.
Similarly, NNAL has long been used in tobacco studies as a bio-
marker to estimate relative NNK exposure, a potent TSNA carcino-
gen which is present in both tobacco and tobacco smoke (IARC,
2007). Our results did not show reductions of NNAL in all groups,
whereas signiﬁcant reductions for the other three TSNAs were
observed in all groups. This apparent anomaly, as previously men-
tioned, adds to the evidence that STP users convert a greater pro-
portion of NNK to NNAL, confounding direct comparisons
between NNK exposure from combustible and non-combustible
tobacco products. Given that NNK conversion to NNAL is a stepin NNK’s detoxiﬁcation metabolic pathway, up-regulation of this
conversion by using STPs is not necessarily a negative aspect, but
rather highlights the limitations of NNAL as a predictive and quan-
titative biomarker in such product switching studies.
The self-reported 15-Item-MNWS-R questionnaire is a measure
of subjective effects of nicotine withdrawal. Day 5 group score
comparisons were all NSD, except the Abstinent group which had
a signiﬁcantly higher score compared to the Dual use and Snus
groups, indicating heightened withdrawal discomfort in the Absti-
nent group.
Several limitations are noted in this trial that are inherent to the
trial design. Most notably, the mandated 60% reduction in CPD
(from baseline) in the Dual use group during intervention may or
may not accurately reﬂect the way consumers’ actually Dual use.
Longer-term ambulatory studies would be required to make this
determination. A second potential limitation may appear to be
the limited group size and duration of the intervention period.
However, with the exceptions of NNAL and 1-OH-pyrene, virtually
all other analytes showed signiﬁcant and substantial reductions,
seemingly validating our statistical plan to detect a 20% change,
80% of the time. While NNAL is known to have a relatively long ter-
minal half-life (17.6 day) (Goniewicz et al., 2009), levels in the
Abstinent group was reduced by -60% after 5 days intervention,
less than most other biomarkers measured, but still suggesting
group size (>25) and intervention duration (5 day) was adequate
to detect the biomarker level changes studied. As previously dis-
cussed, the two exceptions that lacked observable reductions
may be caused by other factors. Lastly, some investigators may
consider not having a ‘positive’ control group, that is, participants
who enter the clinic and continue smoking their UB cigarettes
throughout the trial period, as a limitation. However, in a previous
trial of very similar design, that did include a UB group, no material
changes in product usage and biomarker levels were noted during
the 5 day intervention period (Krautter and Borgerding, 2014).
In summary, we report results from a clinical conﬁnement trial
where cigarette smokers were switched to exclusive or Dual use of
two relatively new types of STPs; Camel-branded Snus and dissolv-
able tobacco Sticks, Strips, and Orbs. Changes in exposure for 32
biomarkers, representing toxicants commonly associated with
tobacco-related morbidity and mortality, were measured after
5 days. As expected, because many of the biomarkers studied result
directly from the combustion of tobacco, the majority of Day 5 bio-
marker levels were substantially reduced in all exclusive STP users,
reductions generally similar in magnitude to being tobacco absti-
nent, with more modest but generally signiﬁcant reductions seen
in Dual users. Of exception was 1-OH-pyrene which does not
appear to be a reliable surrogate biomarker for PAHs in tobacco
studies. Moderate to substantial reductions of biomarkers endoge-
nous to tobacco (i.e., TSNAs) were also seen, again less so in Dual
users, with the exception of NNAL, a biomarker of exposure that
appears to have limited utility based upon confounding factors in
trials that switch smokers from combustible to non-combustible
tobacco products. Lastly, given the unique nature of DTPs, which
are entirely consumed, we investigated whether such oral inges-
tion causes a shift in urinary to fecal nicotine excretion. Results
suggest no shift occurs and the major excretory pathway remains
urinary excretion, regardless of the route of nicotine exposure. It
is noted however, levels of T-NicEq in his trial analyzed for nico-
tine + 9 metabolites (nic + 9) in urine and feces, known to account
forP90% of systemic exposure in urine when an additional metab-
olite, 4-OH-4-(3-puridyl)-butanoic acid is included (Benowitz
et al., 2009). Recent advances in urinary analysis has veriﬁed these
earlier estimates, and when 4-OH-4-(3-puridyl)-butanoic acid is
included, total accountability is 95% of the absorbed exposure
(Piller et al., 2014), with 4-OH-4-(3-puridyl)-butanoic acid
accounting for approximately 5% of the T-NicEq. Based on this trial,
G.R. Krautter et al. / Regulatory Toxicology and Pharmacology 71 (2015) 186–197 197the presence of this minor metabolite in feces cannot be
discounted.
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